Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference
OptiNose, Inc. (OPTN)
Last optinose, inc. earnings: 3/5 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.optinose.com
Company Research
Source: GlobeNewswire
YARDLEY, Pa., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 3:00 p.m. ET. To listen to a webcast of this presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 30 days following the conclusion of the event. About Optinose Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn. Optinose Investor ContactJonathan Neelyjonathan.neely@optinose.com267.521.053
Show less
Read more
Impact Snapshot
Event Time:
OPTN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPTN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPTN alerts
High impacting OptiNose, Inc. news events
Weekly update
A roundup of the hottest topics
OPTN
News
- OptiNose, Inc. (NASDAQ: OPTN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- OptiNose, Inc. (NASDAQ: OPTN) had its price target raised by analysts at Lake Street Capital from $3.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- OptiNose granted FDA nod to expand labeling for sinusitis therapy [Seeking Alpha]Seeking Alpha
- XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps [Yahoo! Finance]Yahoo! Finance
- XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsGlobeNewswire
OPTN
Earnings
- 3/7/24 - Beat
OPTN
Sec Filings
- 3/19/24 - Form 4
- 3/19/24 - Form 4
- 3/19/24 - Form 4
- OPTN's page on the SEC website